MedTrace Logo

Intraventricular Fibrinolysis for Aneurysmal Subarachnoid Hemorrhage.

NCT03187405 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2025-07-25

No results posted yet for this study

Summary

Aneurysmal subarachnoid hemorrhage (SAH) is a devastating form of stroke, with delayed cerebral ischemia (DCI) as a major complication. There are several evidences, both in preclinical and in clinical studies that intraventricular fibrinolysis (IVF) controls the phenomenon that are leading to DCI. Here, the investigators propose to conduct a phase III trial to provide a clear evaluation of the impact of IVF after aneurysmal SAH.

Conditions

  • Subarachnoid Hemorrhage

Interventions

DRUG

EVD + IVF with Alteplase

Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).

Sponsors & Collaborators

  • University Hospital, Caen

    lead OTHER

Principal Investigators

  • Thomas Gaberel, MD, PhD · University Hospital, Caen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-21
Primary Completion
2024-02-05
Completion
2025-02-05

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03187405 on ClinicalTrials.gov